Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients
Journal
Liver International
Journal Volume
27
Journal Issue
2
Pages
235-239
Date Issued
2007
Author(s)
Abstract
Background/Aim: Hepatitis B e antigen (HBeAg) seroconversion is an important event in the natural history of chronic hepatitis B virus (HBV) infection. Whether early dynamics of HBeAg index ratio could predict therapeutic endpoint of HBeAg seroconversion in patients receiving lamivudine remains unclear and thus deserves investigation. Methods: A total of 52 patients (males/females, 40/12; mean age, 31.1±7.5 years) with HBeAg-positive chronic hepatitis B and serum alanine aminotransferase (ALT) level ?5 × upper limit of normal were enrolled. They received daily 100 mg lamivudine for at least 1 year. Pretreatment HBeAg index ratio and the dynamics during treatment [early serologic response (ESR) and serologic breakthrough (SB)] between responders and non-responders were compared. Results: Of these 52 patients, mean pretreatment serum ALT level was 580 IU/l and baseline HBeAg index ratio (S/N) was 37.9. The overall 1-year on-treatment combined response rate was 50%. By using linear regression analysis, HBeAg index ratio was positively correlated with serum HBV DNA level (Pearson's correlation coefficient: 0.62, P <0.0001). By using multivariate logistic regression analysis, ESR could predict the success of treatment response (P = 0.0302), and SB had a 90%5 positive predictive value of treatment failure. Conclusions: HBeAg index ratio is closely correlated with serum HBV DNA level, and the dynamics of HBeAg index ratio may predict 1-year on-treatment combined response to lamivudine in HBeAg-positive chronic hepatitis B patients. ? 2007 Blackwell Munksgaard.
SDGs
Other Subjects
alanine aminotransferase; bilirubin; hepatitis B(e) antigen; lamivudine; virus DNA; alanine aminotransferase; hepatitis B(e) antigen; lamivudine; RNA directed DNA polymerase inhibitor; virus DNA; adult; alanine aminotransferase blood level; antigen detection; article; bilirubin blood level; controlled study; correlation analysis; drug response; drug treatment failure; female; hepatitis B; Hepatitis B virus; human; linear regression analysis; major clinical study; male; multivariate logistic regression analysis; nonhuman; prothrombin time; seroconversion; thrombocyte count; treatment duration; treatment response; virus load; blood; genetics; immunology; prediction and forecasting; statistical model; time; treatment outcome; virology; Adult; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Linear Models; Logistic Models; Male; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome
Type
journal article